CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Contingent Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Contingent Liabilities | ₹634 Cr | ₹567 Cr | ₹743 Cr | ₹622 Cr | ₹761 Cr |
What is the latest Contingent Liabilities ratio of CIPLA ?
Year | Contingent Liabilities |
---|---|
Mar2024 | ₹634 Cr |
Mar2023 | ₹567 Cr |
Mar2022 | ₹743 Cr |
Mar2021 | ₹622 Cr |
Mar2020 | ₹761 Cr |
How is Contingent Liabilities of CIPLA Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹634 Cr | 11.90 | |
Mar2023 | ₹567 Cr | -23.73 | |
Mar2022 | ₹743 Cr | 19.41 | |
Mar2021 | ₹622 Cr | -18.28 | |
Mar2020 | ₹761 Cr | - |
Compare Contingent Liabilities of peers of CIPLA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
CIPLA | ₹132,321.2 Cr | -1.3% | 2.8% | 33.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹443,025.0 Cr | -0.4% | 4.7% | 60.2% | Stock Analytics | |
DIVIS LABORATORIES | ₹144,299.0 Cr | -1.1% | 11% | 43.2% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹108,579.0 Cr | -2.3% | -7.8% | 14.4% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹106,092.0 Cr | -5.7% | -12.6% | 68.7% | Stock Analytics | |
MANKIND PHARMA | ₹97,396.6 Cr | -2.7% | 6.6% | 33.4% | Stock Analytics |
CIPLA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CIPLA | -1.3% |
2.8% |
33.9% |
SENSEX | 0.3% |
3% |
23.3% |
You may also like the below Video Courses